Second-look flexible nephroscopy after percutaneous nephrolithotomy is cost-effective only for patients who have larger residual stone fragments.
Dallas-Second-look flexible nephroscopy after percutaneous nephrolithotomy (PCNL) is cost-effective only for patients who have larger residual stone fragments, according to findings from a study by researchers at University of Texas Southwestern Medical Center, reported at the 2008 AUA annual meeting.
The procedure demonstrated cost-effectiveness only when patients had residual stone fragments larger than 4 mm, said Jay D. Raman, MD, a urology fellow at UT Southwestern under the direction of senior investigator Yair Lotan, MD, associate professor of urology. Thirty-six percent of patients who had smaller stone fragments eventually became symptomatic, and almost 50% of these symptomatic fragments required surgical intervention. In contrast, 67% of patients with stone fragments larger than 4 mm became symptomatic, and all those who became symptomatic required surgical intervention.
At Dr. Raman's institution, the cost of each second-look nephroscopy exceeded the estimated average cost of care for patients with a residual stone fragment by about 40%.
However, he added, the cost analysis model used in the study did not account for the potential benefit of reduced anxiety about future unexpected stone pain afforded by second-look flexible nephroscopy.
PCNL is effective for management of large or complex renal calculi. Although the procedure's goal is a stone-free kidney, a proportion of patients will have residual fragments after an initial PCNL procedure.
"Second-look flexible nephroscopy is not routinely performed to retrieve small, residual fragments because fragments are considered 'clinically insignificant' and because second-look flexible nephroscopy is not viewed as cost effective," said Dr. Raman.
UT Southwestern urologists have questioned whether small, residual stone fragments really are clinically significant. As a result, second-look flexible nephroscopy has become the standard practice.
A second look at "second-look"
To continue the exploration of the role and cost-effectiveness of second-look nephroscopy, Dr. Raman and colleagues reviewed published studies involving 645 patients, of whom 40% had clinically insignificant residual fragments that became symptomatic. In 57% of the cases, the patients subsequently required surgical intervention.
The cost-effectiveness of second-look flexible nephroscopy after PCNL was examined by reviewing the natural history of residual fragments after PCNL at UT Southwestern and creating a cost model based on meta-analysis of published outcomes for clinically insignificant residual stone fragments.
Dr. Raman and colleagues identified 527 patients who underwent PCNL between 1999 and 2007 and who had had at least 6 months' radiographic follow-up. Of those patients, 42 were observed to have residual fragments.
The endpoint of the study was a symptomatic residual-fragment event requiring medical or surgical therapy.
The meta-analysis of published literature yielded an average cost of $1,743 for each patient who had a clinically insignificant fragment. That average cost included lost wages and the costs of the emergency room visit and the surgical intervention. In contrast, second-look nephroscopy cost $2,475 at Dr. Raman's institution.
In the UT Southwestern series, 33 of 42 patients had residual stone fragments of 4 mm or less. During a median follow-up of 41 months, 12 (36%) became symptomatic and five of these (42%) required surgical intervention.
Of the nine patients with larger residual fragments, six (67%) became symptomatic and all six (100%) required surgical intervention.
Dr. Raman said alterations in two assumptions would change the cost-benefit analysis: the likelihood of a symptomatic event and the likelihood that a symptomatic event will require surgical intervention.
A two-way sensitivity analysis showed that second-look nephroscopy would be cost effective for patients with residual stone fragments >4 mm. In those patients, the cost of a symptomatic clinical event and surgical intervention would exceed that of second-look flexible nephroscopy. In different clinical scenarios, the cost of care ranged from $2,552 to $6,172.
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.